

To,

Date: 13.02.2021

BSE Limited P.J. Towers, Dalal Street, Mumbai – 400 001	Metropolitan Stock Exchange of India Limited Vibgyor Towers, 4 th floor, Plot No. C62, Opp. Trident Hotel, BandraKurla Complex, Bandra (E), Mumbai- 400 098
---	---

Dear Sir/Madam,

Sub: Outcome of board meeting under Regulation 30 read with 33 (3) (c) of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015

Ref: (Scrip code: 539267/ DRHABEEB)

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Dr Habeebullah Life Sciences Limited held on Saturday, 13.02.2021 at 3.30 P.M. at the registered office of the Company, the following were considered and approved by the Board:

1. Un-Audited financial results (Standalone & Consolidated) for the quarter ended 31.12.2020.
2. Limited Review Report (standalone & consolidated) along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 31.12.2020.
3. Resignation of Ms. Neha Kankariya as Company Secretary and Compliance officer of the Company w.e.f. 13.02.2021.
4. Appointment of Ms. Deepa Dudani as Company Secretary and Compliance officer of the Company w.e.f 13.02.2021.

Disclosure as required under Reg. 30 of SEBI(Listing Obligations and Disclosure Requirements) 2015 related to appointments and resignation as mentioned above is enclosed hereunder.

The meeting of the Board of Directors commenced at 03:30 P.M. (IST) and concluded at 07.00 P.M (IST).

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Dr Habeebullah Life Sciences Limited


K. Krishnam Raju
Whole-Time Director
(DIN: 00874650)



Encl: as above

Disclosure under Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 related to appointments and resignation as mentioned below:

S. No	Details of events that need to be provided	Information of such event(s)	
1.	Name of the Company Secretary	Ms. Neha Kankariya	Ms. Deepa Dudani
2.	Reason for Appointment/Resignation	Ms. Neha Kankariya Company Secretary and Compliance Officer of the Company has tendered her resignation w.e.f 13.02.2021	Ms. Deepa Dudani was appointed as Company Secretary and Compliance Officer of the Company w.e.f 13.02.2021
3.	Date of Appointment and terms of appointment	--	The Board on the recommendation of the Nomination & Remuneration Committee in its meeting held today was appointed as Company Secretary and Compliance officer of the Company.
4.	Brief Profile (in case of appointment)	--	Ms. Deepa Dudani is a Bcom graduate and a Qualified Company Secretary and has a work experience of around 4.5 years.
5.	Disclosure of relationships between directors	Ms. Neha Kankariya is not related to any Director or KMP and Promoters of the company.	Ms. Deepa Dudani is not related to any Director or KMP and Promoters of the company.
6.	Shareholding, if any in the company	Ms. Neha Kankariya is not holding any shares in the company.	Ms. Deepa Dudani is not holding any shares in the company.

Dr. Habeebullah I. E. Sciences Ltd.



PART-I							(Rs in Lakhs)
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED 31ST DECEMBER, 2020							
Sr.No	Particulars	Quarter ended			Year to date figures		Previous Year ended 31-03-2020
		3 Months ended 31-12-2020	Corresponding 3 months ended in previous year 31-12-2019	Preceding 3 months ended 30-09-2020	For current period 9 Months ended 31-12-2020	For previous period 9 Months ended 31-12-2019	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
I	Revenue from Operations	-	41.51	-	1.30	118.99	143.19
II	Other Income	3.74	4.98	3.64	10.92	10.62	15.82
III	Total Revenue (I+II)	3.74	46.49	3.64	12.22	129.61	159.01
IV	Expenses						
	Cost of Material Consumed	-	6.31	-	0.19	19.46	22.49
	Employee benefits expense	7.52	25.07	12.72	32.48	83.97	125.96
	Depreciation and Amortisation expense	0.26	0.24	0.27	0.79	0.71	1.08
	Other Expenses	14.09	52.23	21.13	53.70	172.52	198.49
	Total Expenses	21.87	83.85	34.12	87.16	276.66	348.02
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(18.13)	(37.36)	(30.48)	(74.94)	(147.05)	(189.01)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(18.13)	(37.36)	(30.48)	(74.94)	(147.05)	(189.01)
VIII	Tax Expense:						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(18.13)	(37.36)	(30.48)	(74.94)	(147.05)	(189.01)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(18.13)	(37.36)	(30.48)	(74.94)	(147.05)	(189.01)
XIV	Other Comprehensive Income						
	A) (i) Items that will not be reclassified to profit or loss						
	(ii) Income Tax related to items that will not be reclassified to profit or loss						
	B) (i) Items that will be reclassified to profit or loss			1.42	1.42		1.85
	(ii) Income Tax relating to items that will be reclassified to profit or loss						
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(18.13)	(37.36)	(29.06)	(73.52)	(147.05)	(187.16)
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)						
	1) Basic	(0.12)	(0.25)	(0.20)	(0.50)	(0.99)	(1.28)
	2) Diluted	(0.12)	(0.25)	(0.20)	(0.50)	(0.99)	(1.28)
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)						
	1) Basic	-	-	-	-	-	-
	2) Diluted	-	-	-	-	-	-
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)						
	1) Basic	(0.12)	(0.25)	(0.20)	(0.50)	(0.99)	(1.28)
	2) Diluted	(0.12)	(0.25)	(0.20)	(0.50)	(0.99)	(1.28)
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1480.87	1,480.87	1,480.87	1,480.87	1480.87


Notes:

- The Unaudited Standalone financial results for the Quarter III and 9 months period ended 31, December 2020 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on February 13, 2021. The Statutory Auditors have carried out the Limited Review of the Unaudited Standalone Financial Results in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015).
- The Unaudited standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (IND AS) 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India ("SEBI") and Regulation 33 of SEBI (LODR) Regulations, 2015 and SEBI Circular dated 05th July, 2016.
- The company has not done any business during this third quarter and yet to start the business. The company is trying to restart the business in due course with restructured business model.
- The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- The figures of the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.
- The results are also available on the website of the Company www.drhl.com

Place : Hyderabad
Date : February 13, 2021

For DR HABEEBULLAH LIFE SCIENCES LIMITED

K. Krishnam Raju
Executive Chairman (DIN 00874650)




PART-I		(Rs in Lakhs)					
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED 31ST DECEMBER, 2020							
S.No	Particulars	Quarter ended			Year to date figures		Previous Year ended 31-03-2020
		3 Months ended 31-12-2020	Corresponding 3 months ended in previous year 31-12-2019	Preceding 3 months ended 30-09-2020	For current period 9 Months ended 31-12-2020	For previous period 9 Months ended 31-12-2019	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
I	Revenue from Operations	-	41.51	-	1.30	118.99	143.19
II	Other Income	3.74	4.98	3.64	10.92	10.62	15.82
III	Total Revenue (I+II)	3.74	46.49	3.64	12.22	129.61	159.01
IV	Expenses						
	Cost of Material Consumed	-	6.31	-	0.19	19.46	22.49
	Employee benefits expense	8.12	29.42	13.32	34.28	93.62	139.96
	Depreciation and Amortisation expense	0.32	0.31	0.33	0.98	0.93	1.63
	Other Expenses	14.21	52.30	21.29	54.13	172.93	200.20
	Total Expenses	22.65	88.34	34.94	89.58	286.94	364.28
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(18.91)	(41.85)	(31.30)	(77.36)	(157.33)	(205.27)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(18.91)	(41.85)	(31.30)	(77.36)	(157.33)	(205.27)
VIII	Tax Expense:						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	(1.04)	-	-	(7.11)
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(18.91)	(41.85)	(30.26)	(77.36)	(157.33)	(198.16)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(18.91)	(41.85)	(30.26)	(77.36)	(157.33)	(198.16)
XIV	Other Comprehensive Income						
	A)						
	(i) Items that will not be reclassified to profit or loss						
	(ii) Income Tax related to items that will not be reclassified to profit or loss						
	B)						
	(i) Items that will be reclassified to profit or loss			1.42	1.42		1.85
	(ii) Income Tax relating to items that will be reclassified to profit or loss						
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(18.91)	(41.85)	(28.84)	(75.94)	(157.33)	(196.31)
XVI	Comprehensive Income attributable to Non Controlling Interest			(0.29)	-		(4.45)
XVII	Comprehensive Income attributable to Owners of the company			(28.55)	(75.94)		(191.86)
XVIII	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)						
	1) Basic	(0.13)	(0.28)	(0.19)	(0.52)	(1.06)	(1.31)
	2) Diluted	(0.13)	(0.28)	(0.19)	(0.52)	(1.06)	(1.31)
XIX	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)						
	1) Basic						
	2) Diluted						
XX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)						
	1) Basic	(0.13)	(0.28)	(0.19)	(0.52)	(1.06)	(1.31)
	2) Diluted	(0.13)	(0.28)	(0.19)	(0.52)	(1.06)	(1.31)
XXI	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1,480.87	1,480.87	1,480.87	1,480.87	1,480.87

Notes:

- The Unaudited consolidated financial results for the Quarter III and 9 months period ended 31, December 2020 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on February 13, 2021. The Statutory Auditors have carried out the Limited Review of the Unaudited Consolidated Financial Results in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015.
- The Unaudited consolidated financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (IND AS) 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India ("SEBI") and Regulation 33 of SEBI (LODR) Regulations, 2015 and SEBI Circular dated 05th July, 2016.
- The company has not done any business during this third quarter and yet to start the business. The company is trying to restart the business in due course with restructured business model.
- The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- The figures of the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.
- The results are also available on the website of the Company www.drhlsl.com

Place : Hyderabad
Date : 13/02/2021

For DR HABEEBULLAH LIFE SCIENCES LIMITED
K. Krishnam Raju
Executive Chairman (DIN 00874650)





A.M. REDDY & D.R. REDDY

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Standalone unaudited quarterly financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


To,
The Board of Directors
Dr Habeebullah Life Sciences Limited
Hyderabad.

1. We have reviewed the accompanying statement of unaudited Standalone financial results of **Dr. Habeebullah Life Sciences Limited** for the period ended 31st December 2020 and the Year to-date results for the period April 01, 2020 to December 31, 2020 ('the statement') attached herewith, being submitted by the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').
2. This Statement, which is the responsibility of the Company's Management and Approved by the Board of Directors, has been Prepared in accordance with the recognition and Measuring Principle laid down in Ind AS 34 'Interim Financial Reporting', Prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting Principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for Financial and accounting matters, and applying analytical and other review procedures. A Review is substantially less in Scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.M REDDY & D.R REDDY
Chartered Accountants
FRN: 009068S




D. Ramakrishna Reddy
Partner

Membership No: 209211

Hyderabad, February 13, 2021.

UDIN: 21209211AAAA BA 7976





A.M. REDDY & D.R. REDDY

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on consolidated unaudited quarterly financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

TO

THE BOARD OF DIRECTORS

Dr.Habeebullah Life Sciences Limited
Hyderabad

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Dr. Habeebullah Life Sciences Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax for the quarter and nine months ended 31st December, 2020 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

1. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the cognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

3. The Statement includes the results of subsidiary Krisani Bio Sciences Limited



4. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. Our conclusion is not modified in respect of this matter.
5. We did not review the financial results of the subsidiaries included in the consolidated unaudited financial results, whose financial results reflect total revenues of Rs. 3.74 Lakhs, for the quarter ended 31st December 2020 and Rs.12.22 Lakhs for the Nine-month period ended 31st December 2020 and total net profit/(loss) after tax of Rs. (18.91) Lakhs for the quarter ended 31st December, 2020 and Rs.(77.36) Lakhs for the Nine month period ended 31st December 2020 and total comprehensive income / loss of Rs. Nil for the quarter ended 31st December 2020 and Nil for the Nine months period ended 31st December 2020. Total comprehensive income/(loss) of Nil for the quarter ended 31st December, 2020, and Rs.(2.86) Lakhs for the Nine-month period ended 31st December 2020 and total comprehensive income of Rs. Nil for the Nine months period ended 31st December 2020 as considered in the consolidated unaudited financial results, whose interim financial statements/financial information/financial results have not been reviewed by us. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion is not modified in respect of this matter.

For A.M REDDY & D.R REDDY

Chartered Accountants

FRN: 009068S


D. Ramakrishna Reddy

Partner

Membership No: 209211

Hyderabad, February 13, 2021.

UDIN: 21209211AAAABB9489

